The art of blocking ADP-ribosyltransferases (ARTs): nanobodies as experimental and therapeutic tools to block mammalian and toxin ARTs
Standard
The art of blocking ADP-ribosyltransferases (ARTs): nanobodies as experimental and therapeutic tools to block mammalian and toxin ARTs. / Menzel, Stephan; Rissiek, Björn; Haag, Friedrich; Goldbaum, Fernando A; Nolte, Friedrich.
in: FEBS J, Jahrgang 280, Nr. 15, 01.08.2013, S. 3543-50.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The art of blocking ADP-ribosyltransferases (ARTs): nanobodies as experimental and therapeutic tools to block mammalian and toxin ARTs
AU - Menzel, Stephan
AU - Rissiek, Björn
AU - Haag, Friedrich
AU - Goldbaum, Fernando A
AU - Nolte, Friedrich
N1 - © 2013 FEBS.
PY - 2013/8/1
Y1 - 2013/8/1
N2 - In 1901, the first Nobel Prize in Physiology or Medicine was awarded to Emil von Behring for his ground-breaking discovery of serum therapy: serum from horses vaccinated with toxin-containing culture medium of Corynebacterium diphtheriae contained life-saving 'antitoxins'. The molecular nature of the ADP-ribosylating toxin and the neutralizing antibodies were unraveled only 50 years later. Today, von Behring's antibody therapy is being refined with a new generation of recombinant antibodies and antibody fragments. Nanobodies, which are single-domain antibodies derived from the peculiar heavy-chain antibodies of llamas and other camelids, are emerging as a promising new class of highly specific enzyme inhibitors. In this review, we illustrate the potential of nanobodies as tools to block extracellular and intracellular ADP-ribosyltransferases (ARTs), using the toxin-related membrane-bound mammalian ecto-enzyme ARTC2 and the actin-ADP-ribosylating Salmonella virulence plasmid factor B toxin of Salmonella enterica as examples.
AB - In 1901, the first Nobel Prize in Physiology or Medicine was awarded to Emil von Behring for his ground-breaking discovery of serum therapy: serum from horses vaccinated with toxin-containing culture medium of Corynebacterium diphtheriae contained life-saving 'antitoxins'. The molecular nature of the ADP-ribosylating toxin and the neutralizing antibodies were unraveled only 50 years later. Today, von Behring's antibody therapy is being refined with a new generation of recombinant antibodies and antibody fragments. Nanobodies, which are single-domain antibodies derived from the peculiar heavy-chain antibodies of llamas and other camelids, are emerging as a promising new class of highly specific enzyme inhibitors. In this review, we illustrate the potential of nanobodies as tools to block extracellular and intracellular ADP-ribosyltransferases (ARTs), using the toxin-related membrane-bound mammalian ecto-enzyme ARTC2 and the actin-ADP-ribosylating Salmonella virulence plasmid factor B toxin of Salmonella enterica as examples.
KW - ADP Ribose Transferases
KW - Amino Acid Sequence
KW - Animals
KW - Bacterial Infections
KW - Bacterial Toxins
KW - Camelids, New World
KW - Drug Delivery Systems
KW - Humans
KW - Molecular Sequence Data
KW - Single-Domain Antibodies
KW - Virulence Factors
U2 - 10.1111/febs.12313
DO - 10.1111/febs.12313
M3 - SCORING: Journal article
C2 - 23627412
VL - 280
SP - 3543
EP - 3550
JO - FEBS J
JF - FEBS J
SN - 1742-464X
IS - 15
ER -